Global Oncology Drugs Market Growth (Status and Outlook) 2025-2031

Global Oncology Drugs Market Growth (Status and Outlook) 2025-2031

The global Oncology Drugs market size is predicted to grow from US$ 234640 million in 2025 to US$ 431450 million in 2031; it is expected to grow at a CAGR of 10.7% from 2025 to 2031.

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.



When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.



Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.



Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

The industry"s leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

LPI (LP Information)' newest research report, the “Oncology Drugs Industry Forecast” looks at past sales and reviews total world Oncology Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Oncology Drugs sales for 2025 through 2031. With Oncology Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncology Drugs industry.

This Insight Report provides a comprehensive analysis of the global Oncology Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oncology Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oncology Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncology Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncology Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Oncology Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others

Segmentation by Application:
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences